Research Analysts’ Recent Ratings Changes for Anavex Life Sciences (AVXL)

A number of firms have modified their ratings and price targets on shares of Anavex Life Sciences (NASDAQ: AVXL) recently:

• 12/1/2025 – Anavex Life Sciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/28/2025 – Anavex Life Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 11/26/2025 – Anavex Life Sciences had its “buy” rating reaffirmed by analysts at D. Boral Capital.
• 11/25/2025 – Anavex Life Sciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Anavex Life Sciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/29/2025 – Anavex Life Sciences had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $46.00 price target on the stock.
• 10/24/2025 – Anavex Life Sciences was downgraded by analysts at Jones Trading from a “buy” rating to a “hold” rating.
• 10/8/2025 – Anavex Life Sciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/7/2025 – Anavex Life Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $42.00 price target on the stock.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.